May 31, 2023
Sana Biotechnology to Present at June 2023 Investor Conferences
May 08, 2023
Sana Biotechnology Announces Preclinical Data Published in Nature Biotechnology Demonstrating its Hypoimmune-Engineered Cells Escape Immune Detection and Survive While Remaining Fully Functional
May 08, 2023
Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates
May 03, 2023
Sana Biotechnology to Present at May 2023 Investor Conferences
May 02, 2023
Sana Biotechnology Announces the Acceptance of Six Abstracts for Presentation at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
Apr 24, 2023
Sana Biotechnology to Host Research & Development Day
Apr 19, 2023
Sana Biotechnology Highlights Preclinical Hypoimmune Data for its Allogeneic CAR T Platform and Advancements with its In Vivo Fusogen Platform with Four Presentations at the 2023 AACR Annual Meeting
Apr 13, 2023
Sana Biotechnology Announces Preclinical Data Published in Nature Communications Demonstrating the Ability of its Hypoimmune Allogeneic CD19-directed CAR T Cells to Evade Immune Rejection and Produce Durable Anti-Tumor Responses
Apr 12, 2023
Sana Biotechnology Announces Preclinical Data Published in Science Translational Medicine Showing its Hypoimmune Pancreatic Islet Cells Evaded Allogeneic and Autoimmune Rejection and Controlled Type 1 Diabetes in Preclinical Model
Apr 10, 2023
Sana Biotechnology Announces the Appointment of Two Pioneers in Drug Discovery and Development to Lead its R&D Organization
Displaying 11 - 20 of 26